RxDoctor Payments DataLook up a doctor →

Lance Lamotte, MD

Interventional Cardiology · Baton Rouge, LANPI 1801856489

Payments from drug & device makers

$23,739in general payments, 2019–2025

Across 476 payments — averaging $49.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Edwards Lifesciences$4K
  • Abiomed$3K
  • Abbott$3K
  • Angiodynamics, Inc.$2K
  • Boston Scientific$1K
  • plus $7K from 38 others

What the payments were for

  • Travel & lodging$9,08138%
  • Food & beverage$14,62462%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,739 in reported general payments places this provider in the 65th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$383,242
Medicare patients
646
Services billed
2,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$256,692
EntrestoSacubitril/Valsartan215$244,747
XareltoRivaroxaban117$117,876
FarxigaDapagliflozin Propanediol29$31,853
Repatha SureclickEvolocumab33$22,250
BrilintaTicagrelor29$16,903
JardianceEmpagliflozin20$13,202
Metoprolol Succinate684$8,338
Repatha SyringeEvolocumab12$7,379
Valsartan220$6,120
Bumetanide140$5,750
Amlodipine-ValsartanAmlodipine Besylate/Valsartan160$5,623
ClopidogrelClopidogrel Bisulfate505$5,323
Nebivolol Hcl115$4,053
Atorvastatin Calcium380$3,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$487$256,692302 claims
NovartisEntresto$701$244,747215 claims
Johnson & JohnsonXarelto$371$117,876117 claims
AstraZenecaFarxiga, Brilinta$228$48,75658 claims
Boehringer IngelheimJardiance$134$13,20220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →